Navigation Links
Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM)
Date:3/2/2010

nd monitor treatment. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral will seek FDA approval for Toraymyxin(TM) and intends to commercialize the product together with EAA(TM). Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
2. First Spaceborne Hyperspectral Imager Will Use QImaging Rolera-MGi EMCCD Camera
3. Spectral appoints new board member
4. Spectral announces second quarter 2009 results
5. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
6. Spectral announces first quarter 2009 results
7. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
8. Spectral announces 2008 financial results
9. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
10. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
11. Spectral announces third quarter 2008 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Pfanstiehl has announced the launch of ... the USA under ICH ... for playing a key role in protein glycosylation.  ... that media supplementation with mannose can improve overall ... to Dr. Christopher Wilcox , VP, Business ...
(Date:10/1/2014)... CA (PRWEB) September 30, 2014 ... user-friendly, cost-effective tools to address sales, training and ... has developed innovative mobile applications to turn ... outlining the agency’s latest customized mobile app creations, ... http://www.studiopmg.com/work . , In partnership with Toyota, StudioPMG ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... available in German . ... quantum dots in a semiconductor layer. Quantum dots are small ... processes. If a short laser pulse is fired at the ... dot experiences a change in the electromagnetic field around it. ... of light by the dot. As soon as the refractive ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2
... Inc. (Nasdaq: VRUS ), a clinical ... commercializing novel drugs to treat viral infections, reported ... quarter ended December 31, 2008. Financial Results ... quarters ended December 31, 2008 and December 31, ...
... Vitro Technologies (Celsis,IVT), a division of Celsis International ... company, and Wisconsin-based Promega Corp,will take the trial ... Celsis IVT is pre-qualifying lots of its ... assays, including,the P450-Glo(TM) CYP Assay used to study ...
... the Clinical and Economic Value of Pharmaceuticals in ... ExL Pharma today announced the start of the ... Marketing for the Pharmaceutical Industry at the Loews ... markets marketers with strategic insights needed to prepare ...
Cached Biology Technology:Pharmasset Reports Fiscal First Quarter 2009 Financial Results 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 4Pharmasset Reports Fiscal First Quarter 2009 Financial Results 5Pharmasset Reports Fiscal First Quarter 2009 Financial Results 6Pharmasset Reports Fiscal First Quarter 2009 Financial Results 7Pharmasset Reports Fiscal First Quarter 2009 Financial Results 8Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 3
(Date:9/30/2014)... have completed the first comprehensive numerical simulation of skeletal ... in an image as data points for the computer ... led by J.S. Chen, the William Prager Professor of ... UC San Diego, presented their findings on the development ... this month. Chen also gave a keynote speech about ...
(Date:9/30/2014)... D.C., September 30, 2014--Sea monkeys have captured the popular ... their easily observable life cycle -- sold as dehydrated ... mate given little more than a tank of salt ... shorter-term pattern: Like other zooplankton, brine shrimp vertically migrate ... coming closer to the surface at night and retreating ...
(Date:9/30/2014)... tetrachloroethylene (PCE) in drinking water may increase the ... a new study led by a Boston University ... published in the journal Environmental Health , ... among 1,766 women in Cape Cod, Ma., where ... the early 1980s by the installation of vinyl-lined ...
Breaking Biology News(10 mins):First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Contaminated water linked to pregnancy complications, BU study finds 2
... unique aroma signature of the durian revered as the ... the world,s foulest smelling food has uncovered several new ... ACS, Journal of Agricultural and Food Chemistry . ... food shops in the United States and elsewhere, has a ...
... in a Duke University-led study contained potentially toxic or untested chemical ... Among the chemicals detected was "Tris," a chlorinated flame ... studies. "Tris was phased out from use in ... it still showed up in 41 percent of the couch foam ...
... Toronto, ON (27 November, 2012) -- A new method of ... The discovery, which transforms aged stem cells into cells that ... to grow cardiac patches for damaged or diseased hearts from ... avoiding the threat of rejection. Stem cell therapies ...
Cached Biology News:Potentially toxic flame retardants found in many US couches 2'Fountain of youth' technique rejuvenates aging stem cells 2
... media and other fluid sources for 8 ... speed of each individual pump is controlled ... are exactly maintained. ,High-precision controlled miniature ... types, which allows flow rates between 0 ...
The Mu-End™ Protein Truncation Kit provides a convenient method for generating a library of N-terminal and C-terminal protein deletions that can be expressed in E. coli....
... cassette is designed to allow ampicillin ... promoter gb2 driving the gene for ampicillin ... the Em7 promoter. It mediates higher transcription ... A synthetic polyadenylation signal terminates the ampicillin ...
... PRO S-7 stirrers deliver accurate ... channels fluids away from internal ... easy-to-use controls which allow users ... ceramic tops feature a chemical ...
Biology Products: